Literature DB >> 16336000

The Personalized Medicine Coalition: goals and strategies.

Edward Abrahams1, Geoffrey S Ginsburg, Mike Silver.   

Abstract

The concept of personalized medicine--that medical care can be tailored to the genomic and molecular profile of the individual--has repercussions that extend far beyond the technology that makes it possible. The adoption of personalized medicine will require changes in healthcare infrastructure, diagnostics and therapeutics business models, reimbursement policy from government and private payers, and a different approach to regulatory oversight. Personalized medicine will shift medical practices upstream from the reactive treatment of disease, to proactive healthcare management including screening, early treatment, and prevention, and will alter the roles of both physician and patient. It will create a greater reliance on electronic medical records and decision support systems in an industry that has a long history of resistance to information technology. Personalized medicine requires a systems approach to implementation. But in a healthcare economy that is highly decentralized and market driven, it is incumbent upon the stakeholders themselves to advocate for a consistent set of policies and legislation that pave the way for the adoption of personalized medicine. To address this need, the Personalized Medicine Coalition (PMC) was formed as a nonprofit umbrella organization of pharmaceutical, biotechnology, diagnostic, and information technology companies, healthcare providers and payers, patient advocacy groups, industry policy organizations, major academic institutions, and government agencies. The PMC provides a structure for achieving consensus positions among these stakeholders on crucial public policy issues, a role which will be vital to translating personalized medicine into widespread clinical practice. In this article, we outline the goals of the PMC, and the strategies it will take to foster communication, debate, and consensus on issues such as genetic discrimination, the reimbursement structures for pharmacogenomic drugs and diagnostics, regulation, physician training and medical school curricula, and public education.

Entities:  

Mesh:

Year:  2005        PMID: 16336000     DOI: 10.2165/00129785-200505060-00002

Source DB:  PubMed          Journal:  Am J Pharmacogenomics        ISSN: 1175-2203


  35 in total

1.  Health care reform: how personalized medicine could help bundling of care for liver diseases.

Authors:  Lopa Mishra
Journal:  Hepatology       Date:  2011-02       Impact factor: 17.425

2.  Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?

Authors:  Harry Enchin
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

3.  The promises of personalized medicine.

Authors:  Ingolf Cascorbi
Journal:  Eur J Clin Pharmacol       Date:  2010-06-19       Impact factor: 2.953

4.  The use of a family history risk assessment tool within a community health care system: views of primary care providers.

Authors:  Carol A Christianson; Karen Potter Powell; Susan Estabrooks Hahn; Susan H Blanton; Jessica Bogacik; Vincent C Henrich
Journal:  J Genet Couns       Date:  2012-01-21       Impact factor: 2.537

5.  National Institutes of Health Center for Regenerative Medicine: putting science into practice.

Authors:  Mahendra Rao
Journal:  Stem Cells Dev       Date:  2013-12       Impact factor: 3.272

6.  Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects.

Authors:  Maria Shoaib; Mansoor Ali Merchant Rameez; Syed Ather Hussain; Mohammed Madadin; Ritesh G Menezes
Journal:  Sci Eng Ethics       Date:  2016-11-28       Impact factor: 3.525

Review 7.  Clinical decision support for genetically guided personalized medicine: a systematic review.

Authors:  Brandon M Welch; Kensaku Kawamoto
Journal:  J Am Med Inform Assoc       Date:  2012-08-25       Impact factor: 4.497

8.  Generalist Genes: Genetic Links Between Brain, Mind, and Education.

Authors:  Robert Plomin; Yulia Kovas; Claire M A Haworth
Journal:  Mind Brain Educ       Date:  2007-03

9.  Epidemiological methods: about time.

Authors:  Helena Chmura Kraemer
Journal:  Int J Environ Res Public Health       Date:  2009-12-31       Impact factor: 3.390

10.  Reading and Generalist Genes.

Authors:  Claire M A Haworth; Emma L Meaburn; Nicole Harlaar; Robert Plomin
Journal:  Mind Brain Educ       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.